News

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also ... Read more

February 17, 2020February 17, 2020

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

News

Daily treatment with a low dose of eRapa, Emtora Biosciences‘ new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led to immune system cell boosting ... Read more

February 12, 2020February 12, 2020

UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

News

A research team at the Abramson Cancer Center of the University of Pennsylvania has been awarded a $500,000 grant from the Alliance for Cancer Gene Therapy (ACGT) to develop ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, ... Read more

February 10, 2020February 10, 2020

Concerto, Pfizer Expand Data Partnership to Include Prostate, Other Cancers

News

Concerto HealthAI and Pfizer Oncology are expanding a collaboration using real-world data (RWD) to advance study design to include a range of cancers, including prostate cancer. The expansion builds ... Read more

January 31, 2020February 14, 2020

Stony Brook Team Given $4.2M Grant to Expand Promising Work in Advanced Prostate Cancer

News

Researchers at Stony Brook University have been awarded a five-year, $4.2 million grant from the National Cancer Institute (NCI) to expand work into promising therapeutic agents against metastatic prostate ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

News

A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — is able to overcome prostate cancer resistance to ... Read more

January 24, 2020February 5, 2020

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests

News

Six regions in the non-coding parts of the DNA that surround FOXA1, a major prostate cancer driver, may be therapeutic targets for lowering the amount of this cancer-promoting protein ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on ... Read more

Pin It on Pinterest